Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.

ABSTRACT: Cancer is classically considered a disease of aging, with over half of all new cancer diagnoses occurring in patients over the age of 65 years. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet the participation of older adults with cancer in ICI trials has been suboptimal, particularly at the extremes of age. Despite significant improvement in treatment response and an improved toxicity profile when compared with conventional cytotoxic chemotherapies, many cancers develop resistance to ICIs, and these drugs are not free of toxicities. This becomes particularly important in the setting of older adults with cancer, who are generally frailer and harbor more comorbidities than do their younger counterparts. Immunosenescence, a concept involving age-related changes

SUBMITTER: Choucair K 

PROVIDER: S-EPMC9438919 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature